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Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging 
studies. The mechanism underlying this is unclear but may be due to N-methyl-D-aspartate 
receptor (NMDAR) hypofunction and parvalbumin (PV) neuronal dysfunction leading to 
disinhibition of mesostriatal dopamine neurons. Here, we develop a translational mouse 
model of the dopamine pathophysiology seen in schizophrenia and test approaches to 
reverse the dopamine changes. Mice were treated with sub-chronic ketamine (30mg/kg) or 
saline and then received in-vivo positron emission tomography of striatal dopamine synthesis 
capacity, analogous to measures used in patients. Locomotor activity was measured using the 
open field test. In-vivo cell-type-specific chemogenetic approaches and pharmacological 
interventions were used to manipulate neuronal excitability. Immunohistochemistry and RNA 
sequencing were used to investigate molecular mechanisms. Sub-chronic ketamine increased 
striatal dopamine synthesis capacity (Cohen’s d=2.5) and locomotor activity. These effects 
were countered by inhibition of midbrain dopamine neurons, and by activation of cortical and 
ventral subiculum PV interneurons. Sub-chronic ketamine reduced PV expression in these 
neurons. Pharmacological intervention with SEP-363856, a novel psychotropic agent with 
agonism at trace amine receptor 1 (TAAR1) and 5-HT1A receptors but no appreciable action 
at dopamine D2 receptors, significantly reduced the ketamine-induced increase in dopamine 
synthesis capacity. These results show that sub-chronic ketamine treatment in mice mimics 
the dopaminergic alterations in patients with psychosis, that this requires activation of 
midbrain dopamine neurons, and can be ameliorated by activating PV interneurons and by a 
TAAR1/5-HT1A agonist. This identifies novel therapeutic approaches for targeting presynaptic 





Schizophrenia is a severe mental disorder and a significant global health burden, highlighting 
the need to better understand its neurobiology in order to develop improved treatments (1). 
Dopaminergic hyperactivity in the striatum is thought to underlie the symptoms of 
schizophrenia, particularly psychosis (2-5). Supporting this, 3,4-dihydroxy-6-18F-fluoro-l-
phenylalanine ([18F]-FDOPA) positron emission tomography (PET) imaging studies have 
revealed higher striatal dopamine synthesis capacity in patients with schizophrenia (6-9). 
Furthermore, increased dopamine synthesis capacity is associated with both the 
development of psychosis (10) and the severity of symptoms (11). Currently available 
antipsychotics are all dopamine receptor blockers, which are inadequate and poorly tolerated 
in many patients, and do not address the mechanism underlying the dopamine dysfunction 
(12, 13). In addition to dopaminergic dysfunction, the glutamate hypothesis of schizophrenia 
has developed from the observations that N-methyl-D-aspartate receptor (NMDAR) 
antagonists such as ketamine induce psychotic symptoms in healthy humans and exacerbate 
symptoms in patients (14, 15). Furthermore,  schizophrenia is associated with a reduction in 
parvalbumin (PV)-expressing GABAergic interneurons, which are regulated by NMDAR in the 
cortex and hippocampus (16-18). It has been suggested that impaired PV neuronal function 
in the cortex and hippocampus may lead to disinhibition of mesostriatal dopamine neuron 
activity via a polysynaptic pathway (19). However, it is not clear if it is possible to develop a 
preclinical model of the increased dopamine synthesis capacity seen in patients using an 
NMDAR antagonist, and whether it is possible to reverse this by targeting PV-expressing 
interneurons or other mechanisms.  
To address this, we tested the effect of sub-chronic ketamine administration on dopamine 
synthesis capacity in mice using the same [18F]-FDOPA PET imaging technique that previously 
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demonstrated elevation in dopamine synthesis capacity in patients (6-9), and also tested the 
potential of activating PV-interneurons to reverse the effects of ketamine on striatal 
dopamine synthesis capacity. We also tested the translational potential of a novel 
psychotropic agent, SEP-0363856 (SEP856), to reverse striatal dopaminergic alterations based 
on evidence that it inhibits ventral tegmental area (VTA) neuronal firing (20). Our objective 
was to develop a chemogenetics/PET approach that is translationally relevant and provides 




















METHODS AND MATERIALS  
All experiments were approved by the UK Home Office under the Animal (Scientific 
Procedures) Act (ASPA) 1986 and Regulation 7 of the Genetically Modified Organisms 
(Contained Use) Regulations 2000. All procedures were performed in accordance with the 
ASPA 1986 and EU directive 2010/63/EU as well as being approved by Imperial College Animal 
Welfare and Ethical Review Body. 
Subjects 
Male mice were 6-8 weeks of age at the time of stereotaxic surgeries and 8-10 weeks of age 
at the start of the experiments. C57BL/6 wild-type, Dopamine transporter (DAT) Cre 
(DAT::Cre) and Parvalbumin (PV) Cre (PV::Cre) mice maintained on a C57BL/6 background 
were used.  
Sub-chronic ketamine regime 
Ketamine hydrochloride solid (Sigma Aldrich) was dissolved in 0.9% saline solution to  6mg/ml 
and injected at a volume of 5ml/kg of body weight, thus administered at a dose of 30mg/kg 
(i.p) once daily for five consecutive days (Figure 1a, Supplementary Figure 1a, Supplementary 
Figure 2a, Supplementary Figure 3a) (21). Control mice received an equivalent volume of 0.9% 
saline vehicle.   
Chemogenetics model  
In DAT::Cre mice AAVs were stereortaxically targeted to the ventral tegmental area (VTA: 
anteroposterior [AP], -3.15mm, mediolateral [ML] ±0.40mm, dorsoventral [DV] -4.30mm) and 
the substantia nigra pars compacta (SNc: AP, -3.15mm, ML ±1.50mm, DV -4.30mm) (Figure 
2b). In PV::Cre mice viruses were stereotaxically injected in pre-limbic cortex (PLc: AP +1.94, 
ML ±0.45, DV -2.20) and in the ventral subiculum (vSub) of the hippocampus (vSub: AP -3.20, 
ML ±2.80, DV -4.30) (Figure 4b). Both the PLc and vSub regions were targeted concurrently 
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for the following reasons. In schizophrenia there are deficits in PV interneuron markers in 
both the prefrontal cortex and in the hippocampus (16, 22-25). Additionally acute and chronic 
ketamine administration is associated with deficits in PV interneuron markers in both regions 
(16, 17, 26-29). The needle was left in place for 3min post injection. Following injections, the 
wound was sutured (Mersilk, 3-1 Ethicon). Two weeks following the surgeries, clozapine N-
oxide (CNO) (0.1mg/kg and 0.5mg/kg, i.p) or saline was administered 30-min before the 
injection of ketamine or saline (Figures 2a, 4a). See supplementary methods for further 
details. 
Open-field test 
Mice were placed into the open field arena for a 20-min habituation period, then injected i.p, 
with either ketamine or saline and placed back in the arena for a further 60-min. Total 
distance travelled was recorded using the Ethovision XT video tracking software system 
(Noldus Information Technologies, Leesburg, VA, USA). For the chemogenetic experiments, 
mice were placed in the open field arenas for 20-min habituation, they then received an 
injection of CNO or saline and activity was recorded for 30-min. Then, mice received an 
injection of ketamine or saline, in line with the treatment schedule, and their activity recorded 
for 60-min. Locomotor activity was assessed on days 1 and 5 of ketamine treatment.  
Positron emission tomography (PET) imaging  
One hour prior to scanning, mice were anaesthetized with isoflurane and underwent external 
jugular vein cannulation. During scanning, the respiration rate was monitored using the 
BioVet physiological monitoring software system (Biovet software; m2m Imaging Corp, 
Cleveland, OH, USA) and body temperature was maintained at 37°C. Mice received 40mg/kg 
(i.p) entacapone (SML0654, Sigma-Aldrich), a catechol-O-methyl-transferase inhibitor, and 
10mg/kg (i.p) benserazide hydrochloride (B7283, Sigma-Aldrich), an aromatic amino acid 
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decarboxylase inhibitor, at 45-min and 30-min before the [18F]-FDOPA respectively. This 
improves brain uptake [18F]-FDOPA by reducing peripheral metabolism of the radiotracer (30). 
SEP363586 (3mg/kg, i.p), a TAAR1/5-HT1A agonist, was provided by Sunovion 
Pharmaceuticals and administered 30-min prior to the [18F]-FDOPA injection. Following 
cannulation, mice were transferred to the bore of an Inveon µPET/CT scanner (Siemens, 
Surrey, UK). Mice underwent a 20-min CT scan for attenuation correction, and then received 
a bolus injection of approximately 4.5MBq [18F]-FDOPA via the external jugular vein cannula 
at the start of the 120-min dynamic PET scan.  
PET analysis  
Inveon Research Workplace software (Siemens USA) was used to draw 3D regions of interest 
(ROIs) manually on summation radioactivity images at the level of the striatum (right and left) 
(0.07cm3) and the cerebellum (0.1cm3) to extract time activity curves (TACs) (Supplementary 
Figure 7) (31). Dopamine synthesis capacity was indexed as the rate constant for the uptake 
and conversion of [18F]-FDOPA to [18F]-dopamine, Ki mod (min-1), and determined using a 
modified Patlak plot accounting for the loss of radioactive metabolites, kloss (30, 32). The 
cerebellum was used as the reference region, in line with the approach used in human studies, 
to account for non-specific uptake as it has negligible dopaminergic projections (33, 34).  
RNA Sequencing (RNA Seq)  
Two days following 5 days of ketamine or saline injections, brains were rapidly removed and 
the PLc was dissected and frozen in isopentane on dry ice. Total RNA was isolated using the 
TriZol reagent (Invitrogen) and purified using RNAeasy micro kits from Qiagen. RNA integrity 
was assessed using the Agilent Bioanalyser and all RNA Integrity number (RIN) values were 
above 8. Then, the cDNA library was prepared using the NEB Next Ultra II Library Prep kit (New 
England Biolabs, USA). Sequencing was conducted on an Illumina HiSeq 2500 system with 100 
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base pair paired-end reads (London, UK). Raw reads were aligned to mm9 genome using 
Tophat version (2.0.11) (35). Gene based counting was performed using the HTSeq counts 
module. Gene expression analysis was performed using the DESeq2 Bioconductor package. 
All genes with adjusted p value of 0.05 or less (calculated from the raw p values using the 
Benjamini and Hochberg algorithm) were considered statistically significant. The RNA seq 
data are available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138802. 
Statistical Analysis 
Statistical analyses were performed using Prism 7.00 software (GraphPad Software, La Jolla, 
California, USA). Normality of distributions was assessed using the Kolmogorov-Smirnov test 
and Levene’s test for equality of variance to guide the choice of statistic. Between-group 
comparisons were made with two-tailed independent samples t-tests for normally distributed 
data, and Mann Whitney U tests were used for non-parametric data. Two-way analysis of 
variance (ANOVA) was used to test the difference in outcome measure between the four 
experimental groups. Locomotor sensitization was analysed with a two-way repeated-
measures ANOVA, with the days as the repeated measure and experimental group as the 
cofactor. Outliers in the data were identified using the Grubbs’s test. Post hoc comparisons 
were Bonferroni corrected.  Cohen’s d effect sizes were calculated using the online calculator 
(http://www.uccs.edu/~lbecker/). Data are expressed as mean ± s.e.m. and statistical 









Sub-chronic ketamine increases dopamine synthesis capacity and locomotor activity 
To test the hypothesis that sub-chronic ketamine administration leads to increased dopamine 
synthesis capacity, mice were injected once daily with ketamine (30 mg/kg) or saline for 5 
consecutive days. Two days after the last ketamine or saline injection in vivo [18F]-FDOPA PET 
imaging was performed. Sub-chronic ketamine treatment significantly increased striatal 
dopamine synthesis capacity compared to controls, with an effect size of d=2.5 (P<0.001, t13= 
4.74) (Figure 1b, c, Supplementary Table 1). We also examined locomotor sensitization, which 
has been used as a behavioural model of the dopaminergic dysfunction seen in psychosis (36). 
Acute ketamine administration (day 1) induced locomotor hyperactivity in the open field test. 
Repeated ketamine administration (day 5) induced locomotor sensitization, an effect that was 
sustained following two-day washout of ketamine (day 7) (Figure 1d, e, f; Supplementary 
Figure 1).  Collectively, these findings indicate that sub-chronic ketamine administration 
induces both an increase in dopamine synthesis capacity and behavioural changes relevant to 
schizophrenia.  
Midbrain dopamine neuron firing is necessary for ketamine-induced increases in dopamine 
synthesis capacity and locomotor activity  
To test if the reported ketamine-induced firing activity of dopamine neurons (37-39), 
underlies the increase in dopamine synthesis capacity we observed, we employed a 
chemogenetic approach to selectively suppress dopamine neuron activity in vivo. We injected 
an adeno-associated virus (AAV) containing a Cre-dependent hM4Di-mCherry fusion protein 
(AAV1-DIO-hM4Di-mCherry) into the ventral tegmental area (VTA) and the substantia nigra 
pars compacta (SNc) of DAT::Cre mice. Cre-dependent expression of hM4Di-mCherry showed 
~98% specificity for dopamine neurons, and CNO-treatment silenced dopamine neuron firing 
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in slice electrophysiology recordings, consistent with our previous findings (Figure 2b-d)(40). 
Administration of CNO prior to ketamine dosing prevented the elevation in striatal dopamine 
synthesis capacity (Figure 2e, Supplementary Table 2) and the ketamine-induced locomotor 
sensitization compared to the relevant control groups  (Figure 2f&g, Supplementary Fig.2). It 
has recently been shown that clozapine, converted from CNO, may have off-target effects at 
endogenous receptors rather than at the DREADDs exclusively (41). Importantly, CNO 
administration in transgenic mice expressing a control construct had no effect on the 
ketamine-induced increase in dopamine synthesis capacity and locomotor activity 
(Supplementary Figure 4), indicating that DREADD-mediated silencing of dopaminergic 
neurons is responsible for the observed effects. Taken together, these findings suggest that 
sub-chronic ketamine increases dopamine synthesis capacity and locomotor sensitization 
through a mechanism that drives firing activity of midbrain dopamine neurons.  
The effect of sub-chronic ketamine on PV expression and function 
Lower levels of PV neurons in the cortex and hippocampus have been observed in 
schizophrenia patients and following acute ketamine treatment (16, 17, 27, 42). In addition, 
it is believed that reduced PV neuron function may lead to changes in dopamine neuron 
activity (19). Therefore, we examined the effects of ketamine on various elements of PV 
interneuron function including PV expression. We found that sub-chronic ketamine treatment 
reduced PV interneuron immunofluorescence in the pre-limbic cortex (PLc) and the ventral 
subiculum (vSub) of the hippocampus (P<0.05, η2 effect size= 0.86) relative to saline controls 
(Figure 3a).  
To investigate the molecular mechanisms underlying the effects of sub-chronic ketamine on 
dopamine synthesis we performed RNA sequencing (RNA Seq) on Plc tissue. We hypothesized 
that sub-chronic ketamine would result in reduced PV expression, and changes in signalling 
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pathways downstream of the NMDA receptor such as calcium signalling and the activation of 
BDNF signalling. Consistent with our a-priori hypotheses, RNA Seq data on PLc tissue revealed 
reductions in the expression of PV (Figure 3b). Moreover, consistent with the hypothesis that 
blocking NMDAR activity increases BDNF signalling (43), we observed a significant increase in 
the expression of genes involved in the pathway downstream of BDNF signalling, specifically 
upregulation of mitogen-activated protein kinase 3 (MAPK3) and RAS, guanyl releasing 
protein 2 (Rasgrp2) (Figure 3b). Additionally, cAMP mediated signalling and calcium signalling 
pathways were significantly activated in ketamine vs saline conditions (Figure 3c). 
Furthermore, using Ingenuity pathway analysis (IPA, QUIAGEN Redwood City, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) L-DOPA was 
the significant upstream regulator of the differentially expressed genes in ketamine vs saline 
conditions (z-score= 2.961, P<0.05, in cortex). Collectively, these data support the hypothesis 
that sub-chronic ketamine increases dopamine synthesis capacity via a pathway that involves 
the inhibition of PV interneuron function. Furthermore, RNA Seq data on PLc tissue did not 
reveal changes in the expression of cholecystokinin (p>0.05), nitric oxide synthase 1 (p>0.05) 
and somatostatin (p>0.05), which are proteins expressed in other GABAergic interneurons. 
Interestingly, consistent with a previous study, vasoactive intestinal peptide receptor 2 
(VIPR2) expression was significantly increased suggesting that other GABAergic interneurons 
may be affected by sub-chronic ketamine administration.  
The role of PV interneuron activity in mediating the effects of sub-chronic ketamine  
Given that ketamine reduced PV expression levels, and the hypothesised role of PV 
interneuron hypofunction in schizophrenia (44, 45), we aimed to determine if activating 
cortical PV interneurons was able to counter the ketamine-induced increase in dopamine 
synthesis capacity. To test this, AAVs expressing a Cre-dependent hM3Dq-mCherry fusion 
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protein were stereotaxically injected into the PLc and vSub of the hippocampus of PV::Cre 
mice (Figure 4a&b). Immunohistochemistry revealed co-localization of mCherry with PV 
immunoreactive neurons and a successful transduction with over 92% specificity in the PLc 
and vSub (Figure 4c&d). In ex vivo slice electrophysiology studies, application of CNO 
depolarised vSub PV neurons expressing mCherry (Figure 4e&f). Using this system, we found 
that in vivo activation of PV interneurons in the PLc and vSub, prior to ketamine 
administration, significantly reduced both the elevation in striatal dopamine synthesis 
capacity (P<0.01, t19= 3.51, two-tailed, Effect size= 1.59) (Figure 4g; Supplementary Table 3) 
and the locomotor effects of acute and sub-chronic ketamine (Figure 4h; Supplementary 
Figure 3). Our results, therefore, suggest that ketamine increases dopamine synthesis 
capacity and locomotor activity via its actions on cortical/hippocampal PV interneurons. 
A novel TAAR1/5-HT1A agonist counteracts the ketamine-induced increase in dopamine 
synthesis capacity 
Our findings suggest that targeting dopamine neuron firing activity may present a viable 
therapeutic target for the increase in dopamine synthesis capacity seen in schizophrenia. One 
potential candidate mechanism is TAAR1 agonism. TAAR1 is a G protein-coupled receptor that 
is expressed throughout monoaminergic brain nuclei including dopamine neurons (46). 
TAAR1 agonists have been shown to reduce dopamine firing rates and release (47-49). In view 
of this, we tested whether SEP-0363856 (SEP856), a novel psychotropic agent with agonism 
at TAAR1 and 5-HT1A(20), counteracts the effect of sub-chronic ketamine treatment on 
dopamine synthesis capacity. Ketamine-treated mice that received SEP856 (3mg/kg, i.p) 
showed significantly lower striatal dopamine synthesis capacity compared to vehicle controls 
(P<0.01, t36= 3.41) (Figure 5). Post hoc analyses showed that Ki mod in ketamine treated mice 
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that received SEP856 was not significantly different from Ki mod in mice not exposed to 


























Our results demonstrate that sub-chronic ketamine administration leads to elevated striatal 
dopamine synthesis capacity, and that this requires the activation of midbrain dopamine 
neurons. The ketamine-induced increase in dopamine synthesis capacity was attenuated by 
the activation of parvalbumin interneurons in the pre-limbic cortex and ventral subiculum, as 
well as by a novel TAAR1/5-HT1A agonist, SEP856. Our study demonstrates for the first time 
to our knowledge that an experimental model induces the same dopaminergic phenotype 
seen in patients with psychosis, and the potential of targeting parvalbumin interneurons and 
a novel TAAR1/5-HT1A agonist to reverse the dopaminergic phenotype.  
The majority of studies show that acute ketamine significantly increases striatal dopamine 
levels (50-53), and elevates VTA dopamine neuron firing (38, 39, 54). Our results extend these 
findings to show that sub-chronic ketamine induces a persistent elevation of dopamine 
synthesis capacity through a mechanism that requires midbrain dopamine neuron firing. 
These results are in line with the increased striatal dopamine synthesis capacity observed in 
schizophrenia patients and were acquired using an equivalent PET imaging technique. It 
should be noted that we investigated dopamine synthesis capacity in the striatum and, 
although it includes nucleus accumbens, most of the signal is from dorsal regions (caudate 
and putamen), (34). Therefore, inferences about the dopamine system elsewhere (eg in 
cortical regions) cannot be made. Additionally, we extend prior findings of reductions in 
parvalbumin levels in the hippocampus and prefrontal cortex following acute or sub-chronic 
ketamine administration (27, 42), to show that ketamine also leads to persistent reductions 
in PV levels and that activation of PV interneurons can attenuate ketamine-induced increases 




Proposed mechanism of action of ketamine on dopamine synthesis capacity 
Ketamine is a non-competitive NMDAR antagonist that binds with high affinity (Ki= 3.1µM) to 
the same binding site as MK801 and PCP (55-57). Parvalbumin interneurons are activated 
upon glutamate binding to NMDAR, and subsequently inhibit the activity of cortical pyramidal 
neurons (58-60). Therefore, by blocking NMDAR, ketamine is thought to reduce the activity 
of parvalbumin interneurons and thereby disinhibit cortical pyramidal neurons, including 
neurons that project to subcortical regions to ultimately disinhibit midbrain dopamine neuron 
firing (19, 38, 61-63). In line with this model of the mechanism of action of ketamine on the 
dopaminergic system, ketamine has been associated with a reduction in parvalbumin 
interneuron function, excessive glutamate release (64-67) and an increase in dopamine 
neuron firing (38, 39, 54). Additionally, lower GABAergic neural activity leads to a reduction 
in PV expression (68, 69) and lower PV expression has been correlated with a reduction in 
coordinated neuronal activity during task performance in rodents (70). Specifically, PV may 
modulate GABA transmitter release by acting as an antifacilitation factor (71), where at lower 
PV concentrations, PV is acting as a buffer and at higher concentrations the free form of PV 
may become functionally relevant to have an effect on synaptic dynamics (72-74). Our 
findings that ketamine’s effects can be reduced by activating parvalbumin interneurons and 
inhibiting midbrain dopamine neurons is consistent with this model. However, it remains 
possible that ketamine has actions on other neuronal populations that contribute to its effects 
on striatal dopamine synthesis capacity. Given the evidence of lower PV levels in the frontal 
cortex and hippocampus in schizophrenia (22-25) and that acute and chronic ketamine 
administration leads to lower PV levels in the frontal cortex and hippocampus (16, 17, 26-29), 
we targeted both regions in our chemogenetics experiment. However, a limitation of 
targeting both regions is that we are not able to distinguish the relative contribution of each 
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region to the effects we observe. Future work targeting each region separately would be 
useful to determine this. Additionally, we investigated the effect of ketamine on PV-positive 
GABAergic interneurons because this subtype has been specifically implicated in 
schizophrenia pathophysiology (16, 17). Notwithstanding this, alterations in other 
interneurons, particularly somatostatin positive interneurons, have also been associated with 
schizophrenia (75). However, we did not see expression changes in cholecystokinin (p>0.05), 
nitric oxide synthase 1 (p>0.05) or somatostatin (p>0.05) in our RNA seq data, suggesting that 
ketamine does not have major effects on these interneurons in the PLc, although we cannot 
exclude effects in other brain regions. In contrast, our RNA seq data revealed a significant 
increase in the expression of vasoactive intestinal peptide receptor 2 (VIPR2) in the PLc. This 
extends a previous finding showing this following acute ketamine administration (76), to 
indicate that VIPR2 expression is also increased after sub-chronic ketamine administration. 
VIPR2 is expressed in somatostatin-positive interneurons and increases excitability of these 
interneurons (76). This finding highlights that other GABAergic interneurons may be affected 
by sub-chronic ketamine treatment and the need for further work to determine if expression 
changes in these interneurons, or others that we were not able to measure such as calretinin 
positive interneurons, contribute to ketamine’s effects on dopamine regulation and 
behaviour.  
Moreover, there is evidence of direct glutamatergic projections from the PLc and other frontal 
regions to the substantia nigra/VTA that activate dopamine neurons and increase locomotor 
behaviour in an NMDAR dependent manner (77, 78). The PLc also projects to the lateral 
habenula (79, 80), which is another major source of glutamatergic projections to the 
rostromedial tegmental nucleus (81). In addition, both the PLc and the ventral subiculum 
(VSub) activate neurons in the amygdala and related regions including the bed nucleus of stria 
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terminalis (BNST), which project to and may activate VTA dopamine neurons (82, 83). 
Glutamatergic projections from the ventral subiculum to the nucleus accumbens also activate 
midbrain dopamine neurons in an NMDAR dependent manner through a pathway involving 
the ventral pallidum (84). Furthermore, glutamatergic projections from the 
pedunculopontine tegmentum (PPTg) to the VTA also activate dopamine neurons (85, 86). 
Thus, our findings could be mediated by direct projections from the PLc to midbrain dopamine 
neurons and/or one or more indirect pathways. Whilst this was outside the translational aims 
of our study, further work is required to test whether pyramidal neuron activity is altered in 
our ketamine model and to characterise the circuit linking cortical and hippocampal 
parvalbumin interneurons to midbrain dopamine neurons.   
Ketamine’s action on receptors other than the NMDAR, could also contribute to the observed 
effects (87). Evidence suggests that ketamine’s antidepressant effects could be independent 
from NMDA receptors expressed in PV interneurons (87) and that deletion of dopamine D2 
receptors from PV interneurons induces hyperlocomotion (88). Additionally, recent findings 
indicate that activation of dopamine D1 receptors on pyramidal cells in the prefrontal cortex 
and/or the action of a metabolite of ketamine on α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors might contribute to its long-lasting antidepressant 
effects (89) (90). However, ketamine’s affinities at other receptors (range of Ki values= 19-
131μM) are considerably lower than its affinity for the NMDAR, and it is not clear if ketamine 
exhibits significant dopamine receptor occupancy in vivo at behaviourally relevant doses (91, 
92). We suggest that the effects of ketamine in our model likely involve NMDAR blockade, but 
a contribution from binding to other receptors cannot be excluded. 
Ketamine has a short half-life (13min) in mice (93) and brain levels of its main metabolite (2R, 
6R)-hydroxynorketamine (HNK), are not detectable 4-hours post administration in mice (90, 
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94, 95). Our PET and behavioural measures were acquired ~48 hours following the last 
ketamine treatment. Thus, it is unlikely that the observed effects are a consequence of direct 
ketamine or HNK action. Previous studies have shown that ketamine induces a release of 
brain derived neurotrophic factor (BDNF) to increase synaptogenesis (95) and elevates MAPK 
signalling (96, 97). This could present a potential mechanism by which ketamine contributes 
to the sustained effects observed in our model.  
Interestingly, whilst CNO significantly reduced locomotor activity compared to baseline, it had 
no effect on dopamine synthesis capacity. It should be noted that locomotor activity was 
measured shortly after CNO administration whilst dopamine synthesis capacity was measured 
2 days following CNO administration. Electrophysiology recordings show that dopamine 
neurons recover quickly upon washout of CNO from solution (40). Thus, our findings indicate 
that CNO does not induce lasting changes in dopamine synthesis capacity, but is able to block 
the effects of ketamine on dopamine synthesis capacity. 
A strength of our study is that it utilized a PET imaging approach that parallels the technique 
used in human studies (6, 30, 33), supporting the translational relevance of the findings. One 
consideration for chemogenetic approaches is the cell-type and regional specificity of 
expression. Injection of viral constructs in wild type mice revealed no detectable expression, 
and CNO administration in transgenic mice expressing a control construct had no effect on 
the ketamine-induced increase in dopamine synthesis capacity and locomotor activity. 
Limitations include that we did not measure other aspects of dopamine function or 
investigate other brain regions. Moreover, we did not test whether the effects of SEP-856 are 
predominately mediated via TAAR1 agonism and its action on dopamine neuron firing, or also 
driven by the compound’s activities at other receptors (20). To date SEP-856 has been tested 
for binding and/or functional activity against multiple panels of known molecular targets (ion 
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channels, G-protein-coupled receptors and enzymes), demonstrating a range of activities at 
several receptors (20). While the most notable functional activity is full agonism at TAAR1 
(EC50 of 0.14 uM), SEP-856 also exhibits binding and agonist activity at the 5-HT1A receptor 
(5-HT1AR), although with lower potency than for TAAR1 (EC50 of 2.3uM) (20). 
Notwithstanding this, attenuation of PCP induced hyperlocomotion by SEP-856 is partially 
blocked by a 5HT1AR antagonist (20), suggesting that its effects in our ketamine model could 
be partly mediated by 5HT1AR. Following our translational work, future pharmacology studies 
will help elucidate the molecular and circuit mechanisms by which SEP-856 attenuates the 
ketamine-induced increase in striatal dopamine synthesis capacity. 
Implications for understanding the pathophysiology of schizophrenia and the 
antidepressant mode of action of ketamine 
PET imaging studies have repeatedly shown elevated dopamine synthesis and release 
capacity in schizophrenia (e.g. (7, 98) and see review (6)), and suggested that this is linked to 
the development of psychosis (99, 100) and changes in cortical glutamate levels (101). 
Moreover, cortical and hippocampal PV interneuron density and PV protein levels have been 
shown to be reduced in schizophrenia (see meta-analysis (25) and (102)). Ketamine induces 
psychotic symptoms in healthy volunteers, and worsens symptoms in patients with 
schizophrenia (14, 15). Our findings indicate that ketamine’s effect on dopamine synthesis 
capacity involves parvalbumin positive interneurons in regions implicated in schizophrenia. 
These findings suggest that inhibition of midbrain dopamine neurons and/or activation of 
cortical parvalbumin interneurons could represent novel therapeutic strategies for 
schizophrenia. Furthermore, our finding that SEP856, a novel TAAR1 agonist, reduces sub-
chronic ketamine-induced elevation in striatal dopamine synthesis capacity provides a proof-
of-concept for pharmacological attenuation of presynaptic dopamine dysfunction. The 
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reduction in PV levels following ketamine in our model was large (Hedge’s g= -2.29), which 
compares to a moderate-large effect size (Hedge’s g=-0.61) reduction in parvalbumin positive 
neuron immunoreactivity reported post-mortem in schizophrenia (102). Thus, our ketamine 
model likely induces more marked effects on parvalbumin than are typically seen in 
schizophrenia. 
Lastly, our data may also have implications for understanding ketamine’s antidepressant 
actions and its abuse potential. There is some evidence that major depression is associated 
with blunted dopaminergic function, including reduced levels of dopamine metabolites post-
mortem and reduced dopamine synthesis capacity (103, 104). Moreover, animal models 
mimicking the neurochemical changes seen in depression exhibit reduced dopamine neuron 
population activity (38). Our findings that sub-chronic ketamine administration elevates 
striatal dopamine synthesis capacity, which persists for several days post dosing, suggest that 
this could contribute to ketamine’s antidepressant actions (48). The majority of pre-clinical 
studies investigating the antidepressant effects of ketamine a 10mg/kg dose of ketamine, but 
doses as high as 50mg/kg have also been used to show antidepressant-like effects (105-110). 
In human studies the optimal therapeutic dose for ketamine is debated, with 0.5mg/kg having  
dissociative, psychotomimetic and antidepressant effects (111, 112), whilst 0.2mg/kg is 
generally considered sub-therapeutic, although one study reported positive therapeutic 
effects with 0.1mg/kg (14, 111, 113). Thus, it would be useful to determine if lower ketamine 
doses than we used also result in persistent increases in dopamine synthesis capacity. It 
should also be noted that other mechanisms, such as augmenting ERK1/MAPK signalling and 
AMPA activity, are also implicated ketamine’s antidepressant actions (114). In line with this 
and previous findings, we show that sub-chronic ketamine administration leads to the 
increase in the expression of genes involved in the pathway downstream of BDNF signalling, 
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such as upregulation of MAPK3  suggesting this could contribute to ketamine’s antidepressant 
effects (96, 97). 
 
Conclusion 
We demonstrate that sub-chronic ketamine leads to an increase in striatal dopamine 
synthesis capacity in the mouse, resembling the dopaminergic alteration seen in patients with 
schizophrenia. Our data suggest that ketamine’s effects on dopamine synthesis capacity are 
mediated by inhibition of PV interneurons in the cortex and ventral subiculum as well as 
activation of midbrain dopamine neurons, and that these alterations can be attenuated by a 
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Legends for figures 
Figure 1: Sub-chronic ketamine increases dopamine synthesis capacity and locomotor 
activity. (a) Schematic showing the drug treatment schedule used to study the effect of sub-
chronic ketamine administration on striatal presynaptic dopamine synthesis capacity and 
locomotor activity in the mouse. (b) [18F]-FDOPA PET brain image (averaged from 20 to 90 
minutes) demonstrating high signal to noise ratio specificity in striatal uptake coregistered to 
the CT mouse brain image from mice treated with saline or ketamine. Standardized uptake 
value (SUV) activity is presented as summed activity over the timeframe (20min-90min) used 
to measure dopamine synthesis capacity (indexed as the uptake rate constant Ki mod). (c) 
Striatal dopamine synthesis capacity (Ki mod/minute) is significantly increased in the ketamine-
treated (n=8) group versus control (n=7) group (***P<0.001, two-tailed, Cohen’s d=2.5, t13= 
4.74)). (d) Total distance travelled during 30min post drug administration. There was a 
significant effect of group (F (1, 26) = 46.21, P<0.0001), day (F (2, 52) = 23.27, P<0.0001) and group 
x time interaction (F (1, 26) = 20.79, P<0.001; Bonferroni post hoc (* = Saline vs ketamine; # = 
day 1 vs day 5), showing that ketamine induces hyperlocomotion. (e) Sub-chronic ketamine 
induces locomotor sensitization (***P<0.001). (f) Locomotor sensitization is sustained 
following a two-day washout of ketamine. Ketamine induced significantly higher locomotor 
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activity in mice that had received sub-chronic ketamine as compared to mice that had 
received saline for 5 days (**P<0.01). Data represent mean ± S.E.M. ***P<0.001, **P<0.01. 
Abbreviations: PET- positron emission tomography, CT- computed tomography 
Figure 2: Midbrain dopamine neuron firing is necessary for ketamine-induced increases in 
dopamine synthesis capacity and locomotor activity. (a) Experimental timeline and drug 
treatment paradigm used to assess the effect of midbrain dopamine neuron inhibition on the 
sub-chronic ketamine-induced increase in striatal presynaptic dopamine synthesis capacity 
and locomotor activity. Two weeks after stereotaxic injection of AAV-hM4Di-mCherry, mice 
received 0.1mg/kg CNO or vehicle followed by ketamine (30mg/kg) or vehicle 30min later for 
5 consecutive days. Mice underwent a dynamic PET/CT scan two days after the last drug 
administration. (b) Bilateral infusion of AAV-hM4Di-mCherry into the VTA and SNc of DAT-Cre 
mice was used to selectively express DREADD receptors in dopamine neurons. (c) 
Fluorescence confocal images of representative midbrain fields depicting coexpression 
(white) of mCherry (magenta) and TH immunofluorescence (green). (d) Percentage of TH+ 
neurons co-expressing mCherry (47 out of total 65 TH+ neurons; 71.7 ± 11 %) and percentage 
of mCherry+ which do not express TH (1 out of total 48 mCherry + neurons, 1.5 ± 1.5%) in the 
ventral tegmental area. Percentage of TH+ neurons co-expressing mCherry (47 out of total 52 
TH+ neurons; 89.6% ± 5.4) and percentage of mCherry+ which do not express TH (1 out of 
total 48 mCherry+ neurons, 1.5 ± 1.5 %) in the SNc. (e) Striatal dopamine synthesis capacity 
(Ki mod /minute) is significantly reduced in CNO/Ket compared to Sal/Ket group (***P<0.001) 
(Sal/Sal (n=12), CNO/Sal (n=13), Sal/Ket (n=12) and CNO/Ket-treated (n=11) groups). (f) Total 
distance travelled during 30min post drug administration. Sub-chronic ketamine treatment 
induced locomotor sensitization that was prevented by inhibition of midbrain dopamine 
neuron firing prior to ketamine treatment. (g) Percentage locomotor sensitization between 
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day1 and day 5. Data represent mean ± S.E.M. ****P<0.0001, ***P<0.001, **P<0.01, 
*P<0.05. Abbreviations: Sal- saline, Ket- ketamine, CNO- clozapine N-oxide, TH- tyrosine 
hydroxylase, PET- positron emission tomography; CT- computed tomography; VTA- ventral 
tegmental area; SNc- substantia nigra pas compacta. 
Figure 3: Sub-chronic ketamine reduces parvalbumin interneuron function. (a) Schematics 
of the location of the PLc and vSub of the hippocampus in the brain. Representative 
fluorescence confocal images of pre-limbic cortex and ventral subiculum (vSub) of the 
hippocampus fields respectively depicting PV interneuron immunofluorescence (green) in 
control (Control) and ketamine-treated (Ketamine) mice. PV immunofluorescence in the PLc 
and vSub of the hippocampus is significantly reduced in the ketamine versus saline group 
(Two-way repeated measures ANOVA significant effect of treatment, F1, 8= 47.28, p<0.001, η2 
Effect size= 0.86; followed by Bonferroni post hoc tests (P<0.05); n=5 mice per group). (b) 
Differential expression of the PV gene in ketamine treated mice vs saline treated controls. 
Differential expression of RASGRP2 and MAPK3 genes in ketamine treated mice vs saline 
treated controls. Log2 fold change is shown in each respective bar.  (c)  Increased activity in 
the calcium signalling and cAMP-mediated signalling pathways in ketamine-treated vs control 
group. Data represent mean ± S.E.M. *P<0.05. Abbreviations: PLc- pre-limbic cortex; vSub- 
ventral subiculum of the hippocampus; PV-parvalbumin.  
Figure 4: In vivo parvalbumin interneuron activation attenuates the effects of sub-chronic 
ketamine-induced increase in dopamine synthesis capacity and locomotor activity. (a) 
Experimental timeline and drug treatment schedule used to study the effect of PV neuron 
activation on the sub-chronic ketamine-induced increase in striatal presynaptic dopamine 
synthesis capacity. Two weeks following stereotaxic injection of AAV-hM3Dq-mCherry, mice 
received 0.5mg/kg CNO or vehicle, followed by ketamine (30mg/kg) or vehicle treatment 
33 
 
30min later for 5 consecutive days. Mice underwent a dynamic PET/CT scan two days 
following the last drug administration. (b) Bilateral infusion of AAV-hM3Dq-mCherry into the 
PLc and vSub of PV-Cre mice was used to selectively express DREADD receptors in 
parvalbumin interneurons. (c) Representative fluorescence confocal images of PLc and vSub 
fields depicting coexpression (white) of mCherry (magenta) and parvalbumin 
immunofluorescence (green). (d) Percentage of PV+ neurons co-expressing mCherry (120 out 
of total  177 PV+ neurons; 65 ± 4.4%) and percentage of mCherry+ which do not express PV 
(9 out of total 129 mCherry+ neurons, 5.8 ± 2.9 %) in the PLc. Percentage of PV+ neurons co-
expressing mCherry (51 out of total 71 PV+ neurons; 72.9 ± 6.3 %) and percentage of 
mCherry+ which do not express PV (5 out of total  59 mCherry + neurons, 7.8 ± 5.2%) in the 
vSub. (e) Effect of 5mM CNO on membrane potential measured in voltage clamp 
configuration from a whole-cell recording of PV interneuron within the vSub from a PV-Cre 
mouse injected with AAV-hM3Dq-mCherry. (f) Change in membrane potential with positive 
showing increase relative to the baseline indicative of PV neuron depolarization upon CNO 
application. (g) Striatal dopamine synthesis capacity (Ki mod /minute) is significantly reduced in 
CNO/ketamine-treated (n=11) (purple) versus SAL/Ket (n=11) (red) group, unpaired t-test 
(**P<0.01, t19= 3.51, two-tailed, Effect size= 1.59). (h) Total distance travelled during a 30min 
test period post drug administration. Sub-chronic ketamine treatment induced locomotor 
sensitization, which was not prevented by activation of parvalbumin interneuron firing prior 
to ketamine treatment (F1, 44 =15.51, *** P<0.001, Bonferroni post-hoc test ** P<0.01 *** 
P<0.001 = day 1 vs day 5). On day 5 activation of parvalbumin interneuron firing prevented 
the effects of sub-chronic ketamine on locomotor activity (F 3, 44 = 9.283, ***P<0.001, 
Bonferroni post-hoc test ***P<0.001 Sal/Ket vs all other groups). Data represent mean ± 
S.E.M. ****P<0.001, **P<0.01. Abbreviations: Sal- saline, Ket- ketamine, CNO- clozapine N-
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oxide, PET- positron emission tomography; CT- computed tomography; PLc- pre-limbic cortex, 
vSub- ventral subiculum of the hippocampus 
Figure 5:  The novel trace amine receptor 1 agonist SEP-0363856 (SEP856) attenuates the 
ketamine-induced increase in dopamine synthesis capacity. Striatal dopamine synthesis 
capacity (Ki mod /minute) was significantly reduced in the ketamine model following the 
administration of SEP compared to vehicle in the ketamine model. Ket/SEP (n=9) (Magenta) 
versus Ket/Veh (n=8) (red) group *P<0.05. Abbreviations: Sal- saline, Ket- ketamine, Veh- 
vehicle, SEP- SEP-0363856 
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